Dostarlimab: Review on success story and clinical trials
ScienceDirect.com - 08 Jan 2025Dostarlimab: Review on success story and clinical trials ...
dostarlimab
Dostarlimab: Review on success story and clinical trials ...
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
OncLive - 28 Apr 2025Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma
BMC Cancer - 01 Jul 2025STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma ...
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
CancerNetwork - 16 Dec 2024Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
Pharmacy Times - 28 Apr 2025AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment ...
A New Immune Treatment May Work Against Several Cancer Types
Time Magazine - 28 Apr 2025A New Immune Treatment May Work Against Several Cancer Types ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
CancerNetwork - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
CancerNetwork - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer
OncLive - 02 Jun 2025Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer ...
Niraparib/Dostarlimab Shows Promise in BRCA+ ER+/HER2– Breast Cancer
CancerNetwork - 13 Dec 2024Niraparib/Dostarlimab Shows Promise in BRCA+ ER+/HER2– Breast Cancer ...
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer
OncLive - 26 Mar 2025Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer ...
Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer
CancerNetwork - 02 Jun 2025Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer
CancerNetwork - 20 Dec 2024Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer ...
Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer
OncLive - 20 Dec 2024Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer ...
Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
OncLive - 03 Jun 2025Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma ...